Camrelizumab-Famitinib Combination Shows Superior Survival Outcomes in Phase III Cervical Cancer Trial
核心洞察
A Phase III trial presented at ESMO 2025 demonstrated that camrelizumab plus famitinib significantly improved progression-free survival (11.1 vs 7.5 months) and overall survival (34.4 vs 23.4 months) compared to platinum-based chemotherapy in recurrent or metastatic cervical cancer (搜索) patients.
The chemotherapy-free combination offers a potential breakthrough for cervical cancer (搜索) treatment by targeting both PD-1 (搜索) and VEGF (搜索) pathways, providing durable disease control with outpatient convenience.
The regimen showed consistent efficacy across PD-L1 (搜索)-positive and negative subgroups, with 93% of patients having a PD-L1 combined positive score ≥1, supporting its broad therapeutic potential.
A Phase III clinical trial evaluating the combination of camrelizumab and famitinib has demonstrated significant survival benefits over standard platinum-based chemotherapy in patients with recurrent or metastatic cervical cancer (搜索) (RMCC), potentially offering the first chemotherapy-free treatment option for this challenging malignancy. The results were presented at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany.
Breakthrough Results in Cervical Cancer Treatment
The randomized, open-label Phase III study (NCT04906993) conducted across multiple centers in China evaluated Jiangsu Hengrui Pharmaceuticals (搜索)' camrelizumab, a PD-1 (搜索) inhibitor, combined with famitinib, an oral multikinase inhibitor targeting VEGFR (搜索)/PDGFR (搜索)/c-Kit (搜索), versus platinum-based chemotherapy as first-line therapy for RMCC.
At a median follow-up of 19.3 months, the combination therapy significantly improved progression-free survival (PFS) compared with chemotherapy, achieving 11.1 months versus 7.5 months (HR 0.68; 95% CI, 0.53-0.86; one-sided p=0.0007). More notably, overall survival showed a substantial benefit of 34.4 months versus 23.4 months for chemotherapy (HR 0.65; 95% CI, 0.49-0.86; one-sided p=0.0012).
Addressing Critical Unmet Medical Need
Recurrent or metastatic cervical cancer (搜索) remains one of the most challenging malignancies to treat, with median overall survival rarely exceeding 13 to 17 months despite recent advances. Since the landmark KEYNOTE-826 study established Merck & Co (搜索)'s Keytruda (pembrolizumab) in combination with platinum-based chemotherapy with or without Roche's Avastin (bevacizumab) as the global first-line standard, continued reliance on cytotoxic chemotherapy has limited tolerability and access, particularly in regions where infusion-based treatment poses logistical and economic barriers.
Synergistic Mechanism of Action
The combination leverages a biologically synergistic approach by simultaneously targeting PD-1 (搜索) and VEGF (搜索) signaling pathways. By blocking VEGF-mediated immunosuppression, famitinib can normalize tumor vasculature and enhance T-cell infiltration, augmenting the anti-tumor effects of PD-1 blockade through camrelizumab. Earlier phase II data in pretreated cervical cancer (搜索) showed an objective response rate of 55% and a manageable safety profile, supporting progression to phase III testing.
Broad Efficacy Across Patient Subgroups
The combination demonstrated consistent efficacy across PD-L1 (搜索)-positive and negative subgroups, with 93% of patients having a PD-L1 combined positive score (CPS) ≥1. This broad activity supports a distinct biologic mechanism and reinforces the rationale for targeting VEGF (搜索)-mediated immune suppression in cervical cancer (搜索).
Safety Profile and Tolerability
Safety findings were consistent with the known profiles of PD-1 (搜索) and VEGF (搜索) inhibitors. Grade ≥3 treatment-related adverse events occurred in 87.3% versus 67.1% of patients in the experimental and control arms, respectively, while discontinuation rates were 13.6% versus 6.6%. Hypertension, proteinuria, and hand-foot syndrome were the most frequent toxicities, though cytopenias and gastrointestinal effects were lower than with chemotherapy and were generally manageable through dose adjustments and supportive care.
Clinical Implications and Expert Perspective
Dr. Domenica Larusso, director of the gynaecological oncology unit at Humanitas Hospital San Pio X, noted limitations in the control arm, including low use of Avastin at 30% and the absence of immunotherapy. However, she acknowledged that consistent efficacy across PD-L1 (搜索) subgroups supports a distinct biologic mechanism. The dual immune-angiogenic strategy may also extend to tumors resistant to prior immune checkpoint blockade.
Market Potential and Future Outlook
Camrelizumab is already approved in China across multiple indications, while famitinib holds approval for RMCC. If the study results translate into regulatory approval, the regimen could gain rapid adoption across China and other Asia-Pacific markets where oral and outpatient therapies are favored. According to GlobalData's analyst consensus forecast, camrelizumab and famitinib are projected to achieve global annual sales of $463 million and $108 million by 2031, respectively.
The results suggest the potential for a chemo-free regimen offering durable disease control and outpatient convenience. Should survival data mature positively, the camrelizumab and famitinib regimen could emerge as a highly validated chemo-free immune-antiangiogenic option for RMCC, offering a meaningful advance in both treatment accessibility and therapeutic innovation.